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SUMMARY 22 
Staphylococcus aureus is an invasive bacterial pathogen, and antibiotic resistance has 23 
impeded adequate control of infections caused by this microbe. Moreover, efforts to prevent 24 
human infections with single component S. aureus vaccines have failed.  In this study, we 25 
evaluated the protective efficacy in rats of vaccines containing both S. aureus capsular 26 
polysaccharides (CPs) and proteins.  The serotypes 5 CP (CP5) and 8 CP (CP8) were conjugated 27 
to tetanus toxoid and administered to rats alone or together with domain A of clumping factor A 28 
(ClfA) or genetically detoxified alpha toxin (dHla).  The vaccines were delivered according to a 29 
preventive or a therapeutic regimen, and their protective efficacy was evaluated in a rat model of 30 
osteomyelitis. Addition of dHla (but not ClfA) to the CP5 or CP8 vaccine induced reductions in 31 
bacterial load and bone morphologic changes compared with immunization with either conjugate 32 
vaccine alone.  Both the prophylactic and therapeutic regimens were protective.  Immunization 33 
with dHla together with a pneumococcal conjugate vaccine used as control did not reduce 34 
staphylococcal osteomyelitis. The emergence of unencapsulated or small colony variants during 35 
infection was negligible and similar for all of the vaccine groups.  In conclusion, addition of 36 
dHla to a CP5 or CP8 conjugate vaccine enhanced its efficacy against S. aureus osteomyelitis, 37 
indicating that the inclusion of multiple antigens will likely enhance the efficacy of vaccines 38 
against both chronic and acute staphylococcal disease. 39 
40 
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INTRODUCTION 41 
 42 
Staphylococcus aureus is a medically important opportunistic pathogen that affects 43 
individuals in the hospital setting as well as in the community.  S. aureus can provoke skin and 44 
soft tissue infections, and it can also disseminate to cause invasive life-threatening infections, 45 
including septic arthritis and osteomyelitis (1).  Osteomyelitis is a progressive infection of the 46 
bone marrow and cortex and is frequently caused by S. aureus (2).  It is usually preceded by 47 
trauma, other nosocomial infections, orthopedic (3) or maxillofacial surgery (4).  The control of 48 
S. aureus infections in patients with either nosocomial or community-acquired infections has 49 
been hampered by the emergence of methicillin-resistant S. aureus (5-7).  The high worldwide 50 
prevalence of nosocomial MRSA infections was responsible for the intensive use of glycopeptide 51 
therapy (8).  Although glycopeptides have long been used to treat severe MRSA infections, the 52 
increasing prevalence of clinically relevant isolates with reduced susceptibility to vancomycin 53 
(9) and the appearance of MRSA resistant to vancomycin (10) have prompted a search for a 54 
suitable immunoprophylactic approach to prevent S. aureus infections. 55 
 Due to its vast array of virulence factors and the myriad of infection types that it causes, 56 
S. aureus presents a unique challenge for vaccine development.  A number of S. aureus antigens 57 
have been explored as potential vaccine components.  Among these, S. aureus capsular 58 
polysaccharides (CP), which are anti-phagocytic and key for immune evasion, have been utilized 59 
(11).  In a phase III clinical trial a conjugate vaccine including CP serotypes 5 (CP5) and 8 (CP8) 60 
significantly (P = 0.02) reduced the incidence of S. aureus bacteremia in patients receiving 61 
hemodialysis between week 3 and 40 after immunization (12).  However, at the study endpoint 62 
(week 54) the vaccine efficacy was only 26%, which was not statistically significant.  A 63 
confirmatory phase III clinical trial failed to reduce bacteremia in hemodialysis patients 64 
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(unpublished). Because of the complexity of S. aureus and its myriad of virulence factors, the 65 
inclusion of multiple staphylococcal antigens would likely result in a more effective vaccine. 66 
Numerous studies suggest that cell wall-linked surface protein clumping factor A (ClfA) 67 
is a promising antigen for inclusion in a S. aureus multicomponent vaccine. Preclinically, ClfA 68 
was shown to be protective in rodent models of arthritis, sepsis and endocarditis (13-15).  Alpha 69 
toxin (Hla) is a pore-forming exotoxin expressed by S. aureus that is cytolytic for a variety of 70 
cell types, including platelets, endothelial cells, and monocytes (16).  Detoxified Hla induces 71 
protection in murine models of lethal pneumonia, subcutaneous abscess formation, and 72 
peritonitis (17-19).  The next generation S. aureus vaccine may benefit from the inclusion of 73 
both CPs and protein antigens.  The selection of surface antigens for inclusion in an experimental 74 
vaccine is difficult because S. aureus produces a wide array of surface proteins that promote its 75 
virulence but are often redundant in function (20).  Moreover, the immune correlates of 76 
protection against S. aureus infection have not yet been elucidated.   77 
Efforts to prevent staphylococcal osteomyelitis by immunization are few (21).  In this 78 
study, we evaluated the ability of active immunization to reduce the severity of experimental 79 
staphylococcal osteomyelitis, and we compared vaccines that were delivered in a preventive or a 80 
therapeutic fashion.  CP conjugate vaccines were evaluated alone and in combination with S. 81 
aureus ClfA or detoxified Hla for their ability to reduce the bacterial burden associated with the 82 
disease, as well as to reduce the gross morphologic changes that occur in the bone during chronic 83 
staphylococcal infection. 84 
 85 
 86 
 87 
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MATERIALS AND METHODS 88 
 89 
Bacterial strains.  S. aureus clinical strains HU-1 and HU-92a were obtained in 2007 90 
from patients with chronic osteomyelitis at the Hospital de Clínicas José de San Martín, 91 
Universidad de Buenos Aires.  HU-1 is a CC97 strain that produces CP5, and HU-92a is a CC45 92 
strain that produces CP8.  Strains were kept frozen in TSB at -20oC, and S. aureus was routinely 93 
cultured at 37°C for 24 h on Columbia agar supplemented with 2% NaCl to enhance CP 94 
production. Bacterial cells were harvested and suspended to the appropriate density in trypticase 95 
soy broth.  S. aureus HU-1 was used as the challenge strain for the CP5 experiments, and S. 96 
aureus HU-92a was used for the CP8 experiments. 97 
The rat osteomyelitis model.  Outbred Wistar adult rats weighing 280-320 g were 98 
purchased from the vivarium of: a) Facultad de Odontología, Universidad de Buenos Aires; b) 99 
Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, or c) Comisión Nacional de 100 
Energía Atómica, Ezeiza, Buenos Aires. The rats were housed at the vivarium of the Instituto de 101 
Microbiología y Parasitología Médica (IMPaM), Universidad de Buenos Aires and CONICET.  102 
Animal care was in accordance with the guidelines set forth by the National Institutes of Health 103 
(22). The use of the rat osteomyelitis model was evaluated by the “Comisión Institucional para el 104 
Cuidado y Uso de Animales de Laboratorio” (CICUAL), Facultad de Medicina, Universidad de 105 
Buenos Aires, and approved through resolution CD 1938/07. 106 
The rats were anesthetized with ketamine/xylazine, the left tibia was exposed, and a hole 107 
in the bone was made with a high-speed drill using a 0.4 mm diameter bit. Each tibia was 108 
injected with a 5 μl suspension containing ~1x106 CFU S. aureus suspended in fibrin glue 109 
(Tissucol kit 1 ml, Baxter Argentina-AG Vienna, Austria) (23).  Fourteen weeks after bacterial 110 
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challenge, the rats were euthanized by CO2 overdose.  Left and right tibias were excised, and 111 
adjacent tissue, especially at the distal epiphysis, was removed. The following measurements 112 
were made using callipers: a) the distance between the inoculation point and the distal end of the 113 
left tibia (DT); b) the left tibia section diameter at the inoculation site (Di) and the perpendicular 114 
diameter at the same site (Dp); c) Di and Dp were also measured in the uninfected right tibia of 115 
the same rat at the DT determined in the diseased left tibia (control).  The osteomyelitic index 116 
(OI) was determined as follows: OI=[Dp+Di]infected - [Dp+Di]control.  In pilot experiments we 117 
determined that the OI at 7 or 14 wks after injection of sterile Tissucol did not differ significantly 118 
from uninjected tibias.  Therefore, in order to avoid unnecessary discomfort to rats, only the left 119 
tibia was injected, and the OI was determined by subtraction of values from the healthy right 120 
tibia (control).  One cm segments involving the infected bone were crushed and homogenized in 121 
sterile mortars. Homogenates were quantitatively cultured overnight on trypticase soy agar, and 122 
the number of CFU was determined.  Plates were incubated for 48 h to evaluate the CFU number 123 
of S. aureus small-colony variants (SCVs), which were characterized by catalase and coagulase 124 
tests and confirmed by a species-specific PCR (24). The OI, the wild-type S. aureus CFU counts 125 
and the S. aureus SCV CFU counts from each experimental group (infected and control) were 126 
compared.  CP5 and CP8 production by S. aureus recovered from the rat tibias was assessed by 127 
colony immunoblot as described (25).   128 
Vaccination schemes.  Rats were vaccinated according to two different schemes.  In the 129 
preventive scheme, rats were immunized on days 0 and 7.  The rats were challenged by the 130 
intratibial route with S. aureus on day 28. In the therapeutic scheme, rats were vaccinated 21 d 131 
after bacterial challenge and boosted 7 days later (day 28).  For both regimens, the rats were 132 
euthanized by CO2 exposure 14 wks (ca. 98 days) after challenge with S. aureus. 133 
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Immunogens and controls.  Rats were immunized with: Group 1) 10 µg of CP5 or CP8 134 
conjugated to tetanus toxoid [CP5(8)-TT].  Group 2) 10 µg of CP5(8)-TT plus 20 μg of 135 
recombinant ClfA region A, domain N123 (ClfA).  Group 3) 10 µg of CP5(8)-TT plus 20 µg of 136 
purified, genetically detoxified S. aureus α-toxin (dHla).  Group 4) 10 µg of Streptococcus 137 
pneumoniae CP18C conjugated to TT [Spn-TT].  The 18C-TT conjugate is a pre-GMP lot of one 138 
of the conjugates included in a commercial vaccine, and the 18C polysaccharide was fully 139 
characterized and devoid of cell wall polysaccharide contamination.  Group 5) 10 µg of Spn-TT 140 
plus 20 µg ClfA.  Group 6) 10 µg of Spn-TT plus 20 µg dHla.  Group 7) Phosphate buffered 141 
saline (PBS) (control group).  The CP/TT ratios were 1/2.6 for the CP5-TT conjugate and 1/2.2 142 
for CP8-TT conjugate. The vaccine antigens (except PBS) were adsorbed on 200 µg Aluminium 143 
[(AlPO4 or Al(OH)3] and delivered subcutaneously to the rats in a 0.1 ml volume.  CP5-TT, 144 
CP8-TT, dHla and Spn TT (CP18C) were adsorbed on AlPO4, whereas ClfA was adsorbed on 145 
Al(OH)3.  The selection of AlPO4 or Al(OH)3 was based upon intrinsic characteristic of the 146 
antigen (such as the isoelectric point) and the pH of the antigen buffer.  Preliminary experiments 147 
in other settings have shown that the use of AlPO4 or Al(OH)3 did not change significantly the 148 
adjuvant effect or impact on protection (unpublished data). 149 
Antibody determinations.  Blood was collected from all rats by cardiac puncture under 150 
anaesthesia prior to euthanasia, and the serum was stored at -20oC.  Preliminary experiments 151 
showed that the titer of antibodies to CP increased after vaccination, whereas the titer of 152 
antibodies in non-vaccinated rats was undetectable and not modified after 14 weeks.  Therefore, 153 
rats were bled only once at the end of the experiment, and the serum from non-immunized rats 154 
served as the control.  A similar criterion was adopted for other antibody determinations in order 155 
to reduce discomfort and further handling of the animals, as recommended by the CICUAL.  156 
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Serum antibody titers to CP5, CP8, Spn CP18C, ClfA and dHla were determined by ELISA 157 
using Nunc Maxisorp microtiter plates.  Optimal coating conditions were defined for each 158 
antigen to insure optimal adsorption on the plates and to allow reproducible detection of specific 159 
rat serum antibodies. Plates were coated overnight at 4°C with solutions of purified CP5 (1 160 
µg/ml), CP8 (30 µg/ml), Spn CP18C (40 µg/ml), ClfA (1 µg/ml) or dHla (20 µg/ml) in 161 
phosphate buffered saline (PBS).  The plates were blocked with PBS + 1% bovine serum 162 
albumin (BSA) for 30 min at room temperature with agitation. Two-fold dilutions of rat sera 163 
(initial dilution 1:10) were added to the plate and incubated with agitation at room temperature 164 
for 30 min.  After washing, peroxidase-AffiniPure goat anti-rat IgG, Fcγ fragment specific 165 
(Jackson ImmunoResearch Laboratories Inc.; product 112-035-008), diluted 1:5000 in PBS-BSA 166 
+ 0.2% -Tween 0.05% was added, and the plate was incubated with agitation for 30 min at room 167 
temperature.  The color was developed using 4 mg o-phenylenediamine + 0.05% H2O2 in 0.1 M 168 
citrate buffer, pH 4.5, for 15 min in the dark at room temperature. The reaction was stopped with 169 
50 µl 3M HCl and the optical density was recorded at 490 nm relative to 620 nm.  The level of 170 
antibodies present in the sera was expressed in mid-point titers.  Midpoint ELISA titers were 171 
calculated by 4-parameter regression analysis and were defined as the reciprocal of the serum 172 
dilution that produced an absorbance (at 490 nm) equal to 50% of the maximum value. 173 
Statistical analysis.  Bone bacterial burdens and OI values were compared by one-way 174 
ANOVA, and multiple comparisons were performed with the Bonferroni post-test. Prism 5.0 175 
software (GraphPad) was used for all calculations, and P values <0.05 were considered 176 
significant. 177 
 178 
 179 
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RESULTS 180 
 181 
CP5 vaccine experiments - preventive scheme.  Two experiments of identical design 182 
using rats from the same source and vaccinated with preparation from the same lot were 183 
performed.  Since the data from the individual experiments were similar, the results from 184 
identical groups were pooled and presented in Fig. 1.  The validity of the experiment was 185 
confirmed by the significant correlation of the bacterial load and the OI (r = 0.92; p<0.0007) 186 
(Fig. 1C). 187 
The addition of ClfA to CP5-TT slightly reduced the bone bacterial load and the OI 188 
compared to that of rats given CP5-TT alone.  The differences, however, did not reach were not 189 
significant (Figs. 1A and 1B).  The addition of ClfA to the Spn-TT conjugate did not improve the 190 
protective efficacy of the CP conjugate (Figs 1A and 1B), indicating the limitations of ClfA as a 191 
protective immunogen in the osteomyelitis infection model.  Nonetheless, the rats given CP5-TT 192 
+ ClfA show a reduced bacterial burden compared to those animals give Spn-TT + ClfA, 193 
suggesting a role for capsular antibodies in reducing infection.   194 
Of note, the addition of dHla to the CP5-TT preparation produced a significant reduction 195 
in bacterial load compared to that of CP5-TT alone (Fig. 1A, CP5 vs. CP5+dHla, p<0.001).  The 196 
specificity of this synergistic response is demonstrated by the fact that dHla did not improve the 197 
protective efficacy of Spn-TT (Fig. 1A, Spn vs. Spn+dHla).  Rats given the CP5-TT + dHla 198 
vaccine showed significantly fewer CFU/bone than the rats given Spn-TT + dHla (p<0.001).  199 
The relevance of dHla as vaccine antigen was underscored by the fact that rats given the CP5-TT 200 
+ dHla showed significantly fewer CFU/bone than the rats given CP5-TT + ClfA (p <0.001).  201 
Lattar et al. - 10 
 
The greatest reduction in OI occurred in the rats given the CP5-TT + dHla vaccine (Fig. 1B), but 202 
the reduction in OI did not reach significance. 203 
 204 
CP5 vaccine experiments - therapeutic scheme.  Two experiments of identical design 205 
were performed, and the results were pooled as described above.  The overall results of the 206 
therapeutic vaccine approach correlated with those obtained with the preventive scheme. The 207 
CP-TT conjugates alone showed little effect therapeutically (Fig. 2A).  In contrast to the results 208 
obtained in the prophylactic regimen, however, the addition of ClfA to the CP5-TT preparation 209 
resulted in a modest but significant reduction in the bone bacterial burden compared to that of 210 
CP5-TT alone (p<0.05) (Fig. 2A).  Similar to the results of the preventive vaccine approach, the 211 
therapeutic addition of dHla to the CP5-TT vaccine provided the greatest and most consistent 212 
protection against infection compared to CP5-TT alone or Spn-TT + dHla (p<0.001).  The 213 
greatest reductions in OI (Fig. 2B) occurred in the rats immunized with CP5-TT + dHla, but the 214 
differences did not achieve statistical significance.  The validity of the experiment was confirmed 215 
by the significant correlation of the bacterial load and the OI (r = 0.95; p<0.0009) (Fig. 2C). 216 
 217 
Vaccine antibody levels - CP5 studies. Serum was obtained from experimental and 218 
control groups on the day the rats were euthanized.  Serum antibody titers in the rats immunized 219 
with the antigens used for the CP5 experiments are shown in Fig 3.  Overall, the antibody 220 
responses of the immunized rats were specific for the individual immunogens.  The CP5-TT 221 
antibody response was generally higher than that elicited by the Spn-TT vaccine (Figs. 3A, 3B, 222 
3C, and 3D).  Antibody titers resulting from vaccination with either CP conjugate tended to be 223 
higher in the rats immunized therapeutically (Fig. 3B and 3D).  The overall antibody response to 224 
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dHla was greater than that of the other antigens (Fig. 3G and 3H).  However, dHla antibody titers 225 
in rats immunized with antigens other than dHla were also somewhat higher than those of the 226 
heterologous antigens, particularly in the rats immunized therapeutically (Fig. 3H).  These data 227 
suggest that dHla is an immunodominant protein elicited during staphylococcal infection.  228 
Whether protection against infection mediated by the CP5-TT vaccine administered with dHla is 229 
mediated by antibodies or by immune T cells remains to be determined. 230 
 231 
CP8 vaccine experiments.  Two experiments each were performed using the preventive 232 
and therapeutic vaccination schemes, and the results were pooled as described above.  The 233 
validity of the CP8 experiments was confirmed by the significant correlation of the bacterial load 234 
and the OI (preventive scheme: r = 0.97; p<0.0001; Fig. 4C) (therapeutic scheme: r = 0.95; 235 
p<0.0001) (Fig. 5C). 236 
The results obtained with the CP8 vaccine groups were similar to those obtained with the 237 
CP5 vaccines.  In the preventive scheme, vaccination with CP8-TT + dHla significantly reduced 238 
the bacterial load (p<0.001) and the OI (p<0.05) compared to vaccination with CP8-TT alone 239 
(Figs 4A and 4B).  Similar findings can be seen for rats immunized therapeutically with either 240 
CP8-TT + dHla or CP8-TT alone (Figs. 5A and 5B).  In contrast, the addition of ClfA to the 241 
CP8-TT vaccine did not improve CP8-TT vaccine efficacy.  Of note are the results showing that 242 
when dHla was combined with the Spn-TT, no protection against osteomyelitis was observed.  243 
Thus, the combination of S. aureus CP antigens and dHla provided the best protection against 244 
experimental infection with encapsulated staphylococci. 245 
 246 
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Vaccine antibody levels – CP8 studies.  Specific serum antibody responses to the 247 
various vaccine antigens used for the CP8 experiments are shown in Figure 6.  Overall, the 248 
antibody responses of the immunized rats were specific for the individual immunogens (Figs. 249 
6A, 6B, 6C, and 6D).  Notable differences in antibody titers were not observed in rats immunized 250 
with CP-TT conjugates before or after bacterial challenge (Figs. 6A, 6B, 6C and 6D).  The 251 
antibody responses to dHla in the rats immunized prophylactically (Fig. 6G) were not as striking 252 
as those observed in the CP5 experiments (Fig. 3G).  Within the CP8 experiment, the most 253 
consistent antibody response to Hla was seen in rats immunized therapeutically with dHla given 254 
with CP8-TT or Spn-TT (Fig. 6H).  Whether protection against infection mediated by the CP8-255 
TT vaccine administered with dHla is mediated by antibodies or by immune T cells is not yet 256 
known. 257 
 258 
Emergence of SCVs.  The percent of SCV colonies recovered from the bone cultures of 259 
each rat were quantified.  Despite the chronic nature of the experimental infection (14 wks), the 260 
emergence of SCVs was <1.6% for all of the experimental groups, with a mean recovery of only 261 
0.86%.  Statistical analysis by ANOVA revealed no significant differences among any of the rat 262 
groups within each of the 4 experiments (CP5-preventive, CP5-therapeutic, CP8-preventive or 263 
CP8-therapeutic) (data not shown).  Similarly, cultures from only three rats yielded colonies of S. 264 
aureus that no longer produced CP5 or CP8 (measured by colony immunoblot), and there was no 265 
obvious association between experimental group and loss of CP production. 266 
 267 
 268 
 269 
 270 
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DISCUSSION 271 
 272 
A number of S. aureus target antigens have been evaluated as vaccine components in 273 
preclinical active or passive immunization studies (20, 26-30).  Because capsular antigens 274 
comprise effective vaccines against other encapsulated bacterial pathogens, early efforts in S. 275 
aureus vaccine development focused on these components. Covalent coupling of CP5 and CP8 276 
to protein carrier molecules significantly increases their immunogenicity and T-cell dependent 277 
properties (31-33).   CP5/CP8-based conjugate vaccines alone failed in clinical trials aimed at 278 
reducing bacteremia in hemodialysis patients (34, 35).  Similarly, a vaccine targeting a single 279 
protein (IsdB) failed to reduce surgical wound infections in patients undergoing a median 280 
sternotomy (26, 28, 36).  Because the nature of S. aureus pathogenicity is multifactorial, it is 281 
likely that the protective responses required to prevent infection should necessarily target a 282 
number of virulence factors (37, 38).  The fact that CP-based vaccines induce functional 283 
antibodies that mediate opsonophagocytic killing of encapsulated staphylococci supports the 284 
inclusion of CP5/CP8 in a multicomponent vaccine.  Indeed, CP5 and CP8 conjugates have been 285 
included in a recently developed tetravalent vaccine that has entered phase I/II clinical trials (36).  286 
In the present study, however, vaccination of rats with the CP5 or CP8 conjugates alone did not 287 
significantly diminish the bone bacterial load or the severity of bone infection.  The addition of 288 
staphylococcal proteins (dHla and to a lesser extent ClfA) significantly reduced the bacterial 289 
burden in rats with osteomyelitis. 290 
ClfA is a cell wall-anchored adhesin that mediates S. aureus binding to fibrinogen and 291 
promotes the attachment of S. aureus to biomaterial surfaces, fibrin clots, platelets and damaged 292 
endothelial surfaces (39). This surface protein is conserved among S. aureus isolates and has 293 
shown protective efficacy in diverse animal models (13-15, 40, 41).  A pooled human 294 
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immunoglobulin G preparation (INH-A21, Veronate®) from healthy donors selected for high 295 
antibody titers to S. aureus ClfA and S. epidermidis SdrG failed to protect neonates from 296 
staphylococcal sepsis in a phase III clinical trial (42).  Despite the failure of this passive 297 
immunotherapy, there is sustained interest in ClfA as a vaccine component for active 298 
immunization against S. aureus (43).  We demonstrated the benefit of targeting both CP5 and 299 
ClfA antigens in a mouse mastitis model, in which passive immunization with antibodies to the 300 
two antigens had an additive effect on reducing bacterial burden (44).  In the present study, the 301 
addition of ClfA to the CP5-TT vaccine only reduced the bacterial load in the CP5 therapeutic 302 
regimen. 303 
Alpha toxoid was first suggested as a vaccine component in 1977 when it was shown to 304 
prevent the lethal gangrenous form of S. aureus mastitis in rabbits (45).  Subsequently, a number 305 
of S. aureus vaccines composed of inactivated toxins or their subunits have been evaluated 306 
preclinically, and the results of these studies were reviewed recently (20, 26).  In addition, S. 307 
aureus Hla activates the immune system via a TLR2-independent mechanism whereby NOD2 308 
signaling results in protection against a murine staphylococcal infection (46).  The fact that a 309 
Th17 response is relevant to host defense against S. aureus (47, 48) and that Hla is able to induce 310 
IL-17A in blood (49) has renewed the interest in Hla as vaccine component.  Our results in the 311 
osteomyelitis model support the use of dHla in a multicomponent S. aureus vaccine.  The 312 
addition of dHla to either the CP5-TT or CP8-TT conjugate vaccine provided the most striking 313 
and consistent protection against the severity of experimental osteomyelitis, as well as the 314 
bacterial burden in the infected bone.  Whereas vaccination with dHla plus an irrelevant 315 
polysaccharide vaccine was not protective, the addition of dHla to CP5(8)-TT induced a 316 
significant reduction of the S. aureus bone load and the severity of experimental osteomyelitis, 317 
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supporting a synergistic effect of the two antigens resulting from immunization.  However, only 318 
37% of 76 highly cited animal research studies were replicated in human randomized trials (50). 319 
Similarly, a recent study aimed at evaluating how well research from murine clinical models 320 
mimics human disease indicates that the transcriptional response to inflammatory stresses in 321 
mice is a poor reflection of the human response to similar stresses (51).  Thus, data from animal 322 
models, although informative, are not necessarily predictive of efficacy in humans (47, 48).  323 
Further clinical trials of vaccines that include CP5/8, ClfA and/or dHla are required to ascertain 324 
whether the findings of the present investigation translate into success in humans.   325 
Immunization with CP5(8) may result in production of opsonic antibodies that enhance 326 
phagocytic clearance of S. aureus, whereas immunization with dHla may induce neutralizing 327 
antibodies that reduce the tissue damage associated with infection. S. aureus is a ubiquitous 328 
microbe, and thus it is feasible that the rats were exposed to S. aureus prior to experimental 329 
infection.  This fact may explain the observed elevated baseline antibody levels to Hla in animals 330 
not administered dHla.  Because all of the animals were subjected to experimental infection, the 331 
measurable titers of antibodies to Hla might have resulted from an enhanced response to this 332 
antigen by the rats, compared with the other presumably weaker antigens.  The immunization 333 
schedule utilized was based upon preliminary experiments.  An extended immunization schedule 334 
might have resulted in a better immune response in the immunized rats. Even though the 335 
vaccination schedule might be considered suboptimal, protective efficacy was observed in our 336 
studies, supporting the use of multiple antigens in a S. aureus vaccine. 337 
SCVs, which have been isolated from patients with chronic, recurrent, or antibiotic-338 
resistant diseases (52), are phenotypes that hold low virulence and that are particularly adapted to 339 
the intracellular environment for long-term persistence (53).  Once SCVs have emerged, they are 340 
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very difficult to eradicate (54).  When S. aureus was passaged in vivo in the mouse model of 341 
mastitis under the selective pressure of antibodies to CP5 or CP8, SCVs were recovered in high 342 
numbers from the infected glands.  However, SCVs did not emerge when the mice were treated 343 
with both CP antibodies and monoclonal antibodies to ClfA (Aurexis ®).  In the present study, 344 
only a small percentage of SCVs were recovered from the rats with osteomyelitis, irrespective of 345 
the vaccine antigen(s) administered.  It is likely that the levels of serum antibodies induced by 346 
active immunization with the CP5(8) conjugates were insufficient to generate SCVs. 347 
In conclusion, the addition of S. aureus protein antigens to a capsular conjugate vaccine 348 
enhanced its efficacy in the prevention and therapeutic treatment of experimental S. aureus 349 
osteomyelitis in rats.  ClfA induced only a modest improvement to the efficacy of CP5(8) 350 
conjugate, but dHla induced a significant enhancement of conjugate vaccine efficacy. The 351 
inclusion of vaccine components designed to neutralize staphylococcal toxins and block adhesins 352 
into a multicomponent vaccine preparation may be an effective strategy for the prevention of S. 353 
aureus infections. 354 
 355 
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FIGURE LEGENDS 539 
 540 
Figure 1.  Protective efficacy S. aureus CP5-TT conjugate vaccines administered alone or in 541 
combination with ClfA or dHla.  Groups of 6-8 rats were immunized according to a preventive 542 
scheme (vaccination before bacterial challenge) and challenged by the intratibial route with S. 543 
aureus HU-1.  The effect of immunization on bacterial load (CFU/bone) and OI (mm) are 544 
depicted in panels A and B, respectively.  Each dot represents determinations made on an 545 
individual rat, and the bars represent the geometric means (bacterial load) or the arithmetic 546 
means (OI) of each group.  Comparisons were performed by one-way ANOVA followed by the 547 
Bonferroni post-test, and the P values for relevant comparisons are shown.  Panel C depicts the 548 
correlation of the bacterial load (CFU/bone) and the OI (mm) (Spearman correlation test).  549 
 550 
Figure 2.  Therapeutic efficacy S. aureus CP5-TT conjugate vaccines administered alone or in 551 
combination with ClfA or dHla.  Groups of 7-9 rats were immunized according to a therapeutic 552 
scheme (vaccination after bacterial challenge) and challenged by the intratibial route with S. 553 
aureus HU-1.  The effect of immunization on bacterial load (CFU/bone) and OI (mm) are 554 
depicted in panels A and B, respectively.  Each dot represents determinations made on an 555 
individual rat, and the bars represent the geometric means (bacterial load) or the arithmetic 556 
means (OI) of each group.  Comparisons were performed by one-way ANOVA followed by the 557 
Bonferroni post-test, and P values for relevant comparisons are shown.  Panel C depicts the 558 
correlation of the bacterial load (CFU/bone) and the OI (mm) (Spearman correlation test). 559 
 560 
Figure 3.  Serum antibody levels to CP5, Spn, ClfA and dHla in groups of immunized rats and 561 
controls.  Animals were immunized according to a preventive (A, C, E and G) or a therapeutic 562 
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(B, D, F, and H) scheme. Blood was collected 14 weeks after bacterial challenge. Each bar 563 
represents the arithmetic mean ± SEM.  P values for selected comparisons were determined by 564 
ANOVA for nonparametric data (Kruskal-Wallis test) followed by the Dunn’s multiple 565 
comparison post-test.   566 
 567 
Figure 4.  Protective efficacy S. aureus CP8-TT conjugate vaccines administered alone or in 568 
combination with ClfA or dHla.  Groups of 8-9 rats were immunized according to a preventive 569 
scheme (vaccination before bacterial challenge) and challenged by the intratibial route with S. 570 
aureus HU-92a.  The effect of immunization on bacterial load (CFU/bone) and OI (mm) are 571 
depicted in panels A and B, respectively.  Each dot represents determinations made on an 572 
individual rat, and the bars represent the geometric means (bacterial load) or the arithmetic 573 
means (OI) of each group.  Comparisons were performed by one-way ANOVA followed by the 574 
Bonferroni post-test, and P values for relevant comparisons are shown.  Panel C depicts the 575 
correlation of the bacterial load (CFU/bone) and the OI (mm) (Spearman correlation test). 576 
 577 
Figure 5.  Therapeutic efficacy S. aureus CP8-TT conjugate vaccines administered alone or in 578 
combination with ClfA or dHla.  Groups of 8-9 rats were immunized according to a therapeutic 579 
scheme (vaccination after bacterial challenge) and challenged by the intratibial route with S. 580 
aureus HU-92a.  The effect of immunization on bacterial load (CFU/bone) and OI (mm) are 581 
depicted in panels A and B, respectively.  Each dot represents determinations made on individual 582 
rats, and the bars represent the geometric means (bacterial load) or the arithmetic means (OI) of 583 
each group.  Comparisons were performed by one-way ANOVA followed by the Bonferroni 584 
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post-test, and the P values for relevant comparisons are shown.  Panel C depicts the correlation 585 
of the bacterial load (CFU/bone) and the OI (mm) (Spearman correlation test). 586 
 587 
Figure 6.  Serum antibody levels to CP8, Spn, ClfA and dHla in groups of immunized rats and 588 
controls.  Animals were immunized according to a preventive (A, C, E and G) or a therapeutic 589 
(B, D, F and H) scheme. Blood was collected 14 weeks after bacterial challenge. Each bar 590 
represents the arithmetic mean ± SEM.  P values for selected comparisons were determined by 591 
ANOVA for nonparametric data (Kruskal-Wallis test) followed by the Dunn’s multiple 592 
comparison post-test. 593 
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